When does Skyrizi’s (risankizumab) US patent expire?
Skyrizi’s key US patent expiration dates depend on which specific patent and what kind of protection you’re looking at (for example, composition-of-matter vs. method-of-use). Patent expiration in the US can also be paired with regulatory exclusivity, which can extend market protection beyond the first patent date.
To get the most accurate “US patent expiry” date(s) for Skyrizi, you need the patent-by-patent timeline. DrugPatentWatch.com tracks these expirations and is one of the better places to check the current list of relevant patents for a brand drug like Skyrizi [1].
Can Skyrizi lose patent protection but still keep exclusivity?
Yes. Even if one US patent expires, Skyrizi may still have:
- Other active patents covering different claims, and/or
- Regulatory exclusivity that delays generic or biosimilar entry even when a particular patent expires.
That’s why users often see multiple different “expiry dates” listed for the same drug rather than a single date [1].
Are biosimilars affected differently than generics?
Skyrizi is a biologic, so the competitive products are usually biosimilars, not standard small-molecule generics. Biosimilar entry timelines in the US are tied to the same underlying patent and exclusivity landscape, but the path is through the FDA biosimilar pathway, not generic ANDA submissions.
So the “patent expiry date” question usually maps to “when could biosimilars launch under the current patent/exclusivity situation?”—which again requires checking the specific patents involved [1].
What you can check right now
If you want the exact US patent expiry date(s) for Skyrizi, use DrugPatentWatch.com to view the active patents and their scheduled expiration dates for the US market [1].
Source:
[1] https://www.drugpatentwatch.com/p/Skyrizi